nach oben

Breast Cancer Research

Erschienen in:

01.12.2010 | Short communication

Contribution of biomarkers to personalized medicine

verfasst von: Daniel F Hayes

Erschienen in: Breast Cancer Research | Sonderheft 4/2010

Einloggen, um Zugang zu erhalten

Excerpt

The theme of the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), presided by Dr Richard L Schilsky, was 'Personalizing Cancer Care' [1]. Dr Schilsky noted that 'as oncologists, our focus has always been, and must remain, treating the patient, not the disease. We must each acquire the skills and make the commitment to do so in an optimal way.' …

Schilsky RL: Personalizing Cancer Care: American Society of Clinical Oncology Presidential Address 2009. [http://jco.ascopubs.org/content/27/23/3725.full]

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25: 5287-52312. 10.1200/JCO.2007.14.2364.CrossRefPubMed

Henry NL, Hayes DF: Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006, 11: 541-552. 10.1634/theoncologist.11-6-541.CrossRefPubMed

Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996, 88: 1456-1466. 10.1093/jnci/88.20.1456.CrossRefPubMed

Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005, 23: 2020-2027. 10.1200/JCO.2005.01.112.CrossRefPubMed

Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010, 102: 152-160. 10.1093/jnci/djp477.CrossRefPubMedPubMedCentral

Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009, 101: 1446-1452. 10.1093/jnci/djp335.CrossRefPubMedPubMedCentral

Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO, EGAPP Working Group: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009, 11: 3-14. 10.1097/GIM.0b013e318184137c.CrossRefPubMedPubMedCentral

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25: 118-145. 10.1200/JCO.2006.09.2775.CrossRefPubMed

10.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010, 28: 2784-2795. 10.1200/JCO.2009.25.6529.CrossRefPubMedPubMedCentral

11.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005, 97: 1180-1184. 10.1093/jnci/dji237.CrossRefPubMed

Titel: Contribution of biomarkers to personalized medicine
verfasst von: Daniel F Hayes
Publikationsdatum: 01.12.2010
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe Sonderheft 4/2010
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr2732

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Contribution of biomarkers to personalized medicine

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 4/2010

Designing adjuvant treatment based on biological measurements in the neoadjuvant setting

Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?

Classical peer review: an empty gun

Controversies in Breast Cancer 2010

Emerging breast cancer epidemic: evidence from Africa

Are current development programs realising the full potential of new agents?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie